Inhibrx will head to FDA for bone cancer drug next year after strong data

What health tech stands to gain as pharma goes DTC

When the Trump administration in September debuted TrumpRx.gov as part of its deal with Pfizer at “most favored nation” prices, my mind immediately turned to

Bidding war breaks out as Novo raises Metsera bid to $10bn

Metsera has now received new takeover bids from both Pfizer and Novo Nordisk, and has plumped for a sweetened $10bn offer from the latter.

Incyte, Prelude ink rare blood cancer pact; Merck takes back rights to Prometheus asset

Plus, news about Kaigene, Celltrion, Solid Bio, Terns Pharmaceuticals, Benitec, Pacira, AmacaThera, UCB, Basilea Pharmaceutica, Pfizer, Kura Oncology, Kyowa Kirin, Novavax, Sanofi, Syndexis and Relmada:

Lilly and Novo near White House deal on obesity drug prices

Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in

Novo ups Metsera bid to as much as $10B in attempt to top Pfizer’s new offer

Hours before a pivotal court hearing, Novo Nordisk has increased its offer for obesity biotech Metsera to as much as $10 billion, trying to outdo